GlassScriptPhysician profile
Dona L Gray
NPI 1538260740
$92,067.03
in general payments reported to CMS, 2019-2025
18 companies · $28K in 2025
The $28K reported for 2025 was more than what 94% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $5,869 · 2021: $30.54 · 2022: $96.37 · 2023: $57.12 · 2024: $28K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Travel and Lodging: $8,869 · Food and Beverage: $1,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,735.00 |
| Travel and Lodging | $8,869.22 |
| Food and Beverage | $1,546.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $55,562.68 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $35,629.06 | 2019-2020 | |
| Amgen INC. | $157.06 | 2024-2025 | Tepezza |
| Lilly USA, LLC | $96.53 | 2022-2025 | Zepbound |
| Alexion Pharmaceuticals, INC. | $84.22 | 2025 | Strensiq |
| Abbott Laboratories | $81.17 | 2022-2024 | Freestyle Libre, Freestyle Libre 3 |
| Beta Bionics, INC. | $78.56 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Insulet Corporation | $63.30 | 2019-2024 | Omnipod |
| Dexcom, INC. | $53.65 | 2019-2021 | |
| Medtronic, INC. | $51.65 | 2025 | Minimed 780g |
| Novartis Pharmaceuticals Corporation | $38.91 | 2022-2023 | |
| Valeritas, INC. | $31.47 | 2019 | |
| Novo Nordisk INC | $29.40 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Tandem Diabetes Care, INC. | $27.29 | 2019 | |
| Medtronic Minimed, INC. | $24.29 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $23.81 | 2025 | Rezdiffra |
| Pfizer INC. | $19.89 | 2020 | |
| Corcept Therapeutics | $14.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dona Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.